nach oben

Journal of Gastrointestinal Cancer

Erschienen in:

01.09.2013 | Review Article

Sporadic Carcinoma of the Colon–Rectum in Young Patients: A Distinct Disease? A Critical Review

verfasst von: Andrea Ciarrocchi, Gianfranco Amicucci

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Colon carcinoma is rare in patients under 40 years but incidence is increasing. Results regarding outcome of this age group have been controversial and difficult to interpret. Some authors have reported a worse prognosis related to advanced stage at diagnosis and cancer-aggressive behavior. We tried to assess whether sporadic colon carcinoma in young patients is a distinct disease with different etiology and how this reflects on outcome.

Methods

Most relevant papers published and indexed on PubMed in the last 20 years were reviewed. Epidemiological data were retrieved from the Surveillance, Epidemiology and End Results database and discussed.

Discussion

Stage-specific analyses adjusted for age have demonstrated that prognosis is related to tumor stage regardless of age. Advanced stage is partly due to tumor biology and to delayed diagnosis. Younger patients show a better performance status that allows aggressive multimodal treatment.

Conclusion

Colon carcinoma in young adults appears to be a distinct disease characterized by biological aggressiveness, but prognosis is not worse due to a better performance status at time of surgical intervention.

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin. 2005;55:74–108. doi:10.3322/canjclin.55.2.74.PubMedCrossRef

Yiu HY, Whittemore AS, Shibata A. Increasing colorectal cancer incidence rates in Japan. Int J Cancer. 2004;109(5):777–81. doi:10.1002/ijc.20030.PubMedCrossRef

Haenszel W, Correa P. Cancer of the large intestine: epidemiologic findings. Dis Colon Rectum. 1973;16(5):371–7.PubMedCrossRef

O’Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Rates of colon and rectal cancers are increasing in young adults. Am Surg. 2003;69:866–72.PubMed

Surveillance, Epidemiology, and End Results (SEER) Program (2002) Public use data (1973–1999). Cancer Statistics Branch, Surveillance Research Program, DCCPS. http://www.seer.cancer.gov

Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol. 2001;96:2992.PubMedCrossRef

Yang Z, Kang L, Wang L, Xiang J, Cai G, Cui J, et al. Characteristics and long-term survival of colorectal cancer patients aged 44 years and younger. Clin Transl Oncol. 2012;14(12):896–904.PubMedCrossRef

Dozois EJ, Boardman LA, Suwanthanma W, et al. Young-onset colorectal cancer in patients with no known genetic predisposition: can we increase early recognition and improve outcome? Med (Baltimore). 2008;87:259–63.CrossRef

Savas N, Dagli U, Akbulut S, Yuksel O, Sahin B. Colorectal cancer localization in young patients: should we expand the screening program? Dig Dis Sci. 2007;52(3):798–802.PubMedCrossRef

10.

Bulow S. Colorectal cancer in patients less than 40 yearsof age in Denmark 1943–1967. Dis Colon Rectum. 1982;25:209–14.CrossRef

11.

O’Connell JB, Maggard MA, Livingston EH, et al. Colorectal cancer in the young. Am J Surg. 2004;187:343–8.PubMedCrossRef

12.

Liang JT, Huang KC, Cheng AL, et al. Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age. Br J Surg. 2003;90:205–14.PubMedCrossRef

13.

Kam MH, Eu KW, Barben CP, et al. Colorectal cancer in the young: a 12-year review of patients 30 years or less. Color Dis. 2004;6(3):191–4.CrossRef

14.

Griffin PM, Liff JM, Greenberg RS, Clark WS. Adenocarcinomas of the colon and rectum in persons under 40 years old. A population-based study. Gastroenterology. 1991;100:1033–40.PubMed

15.

Marble K, Banerjee S, Greenwald L. Colorectal carcinoma in young patients. J Surg Oncol. 1992;51(3):179–82.PubMedCrossRef

16.

Mourra N, Zeitoun G, Buecher B, et al. High frequency of chromosome 14 deletion in early-onset colon cancer. Dis Colon Rectum. 2007;50:1881–6.PubMedCrossRef

17.

Liu B, Farrington SM, Petersen GM, Hamilton SR, Parsons R, Papadopoulos N, et al. Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med. 1995;1(4):348–52.PubMedCrossRef

18.

Rajiv VD, Michael PL, Philip BP. Genetic and phenotypic correlates of colorectal cancer in young patients. N Engl J Med. 2000;342:137–8.CrossRef

19.

Messerini L, Vitelli F, De Vitis LR, et al. Microsatellite instability in sporadic mucinous colorectal carcinomas: relationship to clinicopathological variables. J Pathol. 1997;182:380–4.PubMedCrossRef

20.

O’Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Do young colon cancer patients have worse outcomes? World J Surg. 2004;28(6):558–62.PubMedCrossRef

21.

Chauvenet M, Cottet V, Lepage C, Jooste V, Faivre J, Bouvier AM. Trends in colorectal cancer incidence: a period and birth-cohort analysis in a well-defined French population. BMC Cancer. 2011;11:282.PubMedCrossRef

22.

Chiang JM, Yeh CY, Changchien CR, Chen JS, Tang R, Chen JR. Mucinous adenocarcinoma showing different clinicopathological and molecular characteristics in relation to different colorectal cancer subgroups. Int J Colorectal Dis. 2010;25:941–7.PubMedCrossRef

23.

Faivre J, Bedenne L, Boutron MC, Milan C, Collonges R, Arveux P. Epidemiological evidence for distinguishing subsites of colorectal cancer. J Epidemiol Community Health. 1989;43(4):356–61.PubMedCrossRef

24.

Johansen C, Mellemgaard A, Skov T, Kjaergaard J, Lynge E. Colorectal cancer in Denmark 1943–1988. Int J Colorectal Dis. 1993;8(1):42–7.PubMedCrossRef

25.

Schellerer VS, Merkel S, Schumann SC, Schlabrakowski A, Förtsch T, Schildberg C, et al. Despite aggressive histopathology survival is not impaired in young patients with colorectal cancer: CRC in patients under 50 years of age. Int J Colorectal Dis. 2012;27(1):71–9. Epub 2011 Sep 1.PubMedCrossRef

26.

Lin JT, Wang WS, Yen CC, Liu JH, Yang MH, Chao TC, et al. Outcome of colorectal carcinoma in patients under 40 years of age. J Gastroenterol Hepatol. 2005;20(6):900–5.PubMedCrossRef

27.

Wang L, Hollenbeak CS, Stewart DB. Node yield and node involvement in young colon cancer patients: is there a difference in cancer survival based on age? J Gastrointest Surg. 2010;14(9):1355–61. Epub 2010 Jun 29.PubMedCrossRef

28.

Hemminki K, Santi I, Weires M, Thomsen H, Sundquist J, Bermejo JL. Tumor location and patient characteristics of colon and rectal adenocarcinomas in relation to survival and TNM classes. BMC Cancer. 2010;10:688.PubMedCrossRef

29.

Endreseth BH, Romundstad P, Myrvold HE, et al. Rectal cancer in the young patient. Dis Colon Rectum. 2006;49:993–1001.PubMedCrossRef

30.

O’Connell JB, Maggard MA, Liu JH, Etzioni DA, Ko CY. Are survival rates different for young and older patients with rectal cancer? Dis Colon Rectum. 2004;47(12):2064–9.PubMedCrossRef

Titel: Sporadic Carcinoma of the Colon–Rectum in Young Patients: A Distinct Disease? A Critical Review
verfasst von: Andrea Ciarrocchi
Gianfranco Amicucci
Publikationsdatum: 01.09.2013
Verlag: Springer US
Erschienen in: Journal of Gastrointestinal Cancer / Ausgabe 3/2013
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-013-9507-5

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Sporadic Carcinoma of the Colon–Rectum in Young Patients: A Distinct Disease? A Critical Review

Abstract

Introduction

Methods

Discussion

Conclusion

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Onkologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Introduction

Methods

Discussion

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2013

Chemoradiotherapy in the Management of Locally Advanced Squamous Cell Carcinoma Esophagus: Is Surgical Resection Required?

Rectum Sarcoma: Challenging Diagnostic and Therapeutic Modalities

Push Enteroscopy: A Useful Diagnostic Modality for Proximal Small-Bowel Mass Lesions

Obesity, Metabolic Factors, and Colorectal Adenomas: a Retrospective Study in a Racially Diverse New York State Hospital

Photodynamic Therapy in Gastroenterology

A Population-Based Comparison of Overall and Disease-Specific Survival Following Local Excision or Abdominoperineal Resection for Stage I Rectal Adenocarcinoma

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Onkologie